June 22, 2021
With a watchful eye on shifting regulatory landscapes throughout North America, how might investors or operators interpret proposed or enacted
June 16, 2021
With a watchful eye on shifting regulatory landscapes throughout North America, how might investors or operators interpret proposed or enacted
May 26, 2021
Lengthy clinical trials and the siphoning of well-studied, ‘textbook’ psychedelics through a cumbersome medical approval regime are unnecessary in 2021,
May 19, 2021
This week, MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced a partnership with self-help guru Deepak Chopra’s The Chopra Foundation, the first high-profile,
May 12, 2021
Despite Asia’s rich history of psychedelic experience, the state of psychedelic study and commercial exploration varies widely across the continent.
May 4, 2021
Alternative health is a rising trend across all corners of the world; the global psychedelics industry is currently expected to
May 4, 2021
This week, the Multidisciplinary Association for Psychedelic Studies (MAPS) released findings from a groundbreaking Phase 3 clinical trial that suggest MDMA-assisted therapy
April 27, 2021
On 21 April 2021, hundreds of attendees from investment, science and healthcare areas attended the PSYCH Investor Summit: Europe &
April 19, 2021
This month, the Multidisciplinary Association for Psychedelic Studies (MAPS) celebrated a milestone: 35 years of research and advocacy of psychedelics. Founded in
April 14, 2021
The recent surge of interest in psychedelic medicine and research efforts has given rise to a truly 21st-century advent: psychedelic
March 31, 2021
The main exchange for listing psychedelics companies, Horizons Psychedelic Stock Index ETF, has completed its first quarterly rebalance of its holdings.
March 24, 2021
Last week, the Australian government announced it would provide $15m of funding to support research into psychedelic medicines and their
